ATE372112T1 - Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd) - Google Patents

Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd)

Info

Publication number
ATE372112T1
ATE372112T1 AT04709870T AT04709870T ATE372112T1 AT E372112 T1 ATE372112 T1 AT E372112T1 AT 04709870 T AT04709870 T AT 04709870T AT 04709870 T AT04709870 T AT 04709870T AT E372112 T1 ATE372112 T1 AT E372112T1
Authority
AT
Austria
Prior art keywords
amphetamines
adhd
treatment
compositions containing
attention deficit
Prior art date
Application number
AT04709870T
Other languages
German (de)
English (en)
Inventor
Richard Couch
A Michaels
Paul Hodgkins
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Application granted granted Critical
Publication of ATE372112T1 publication Critical patent/ATE372112T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04709870T 2003-02-10 2004-02-10 Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd) ATE372112T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44579303P 2003-02-10 2003-02-10
US47392503P 2003-05-29 2003-05-29

Publications (1)

Publication Number Publication Date
ATE372112T1 true ATE372112T1 (de) 2007-09-15

Family

ID=32871959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709870T ATE372112T1 (de) 2003-02-10 2004-02-10 Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd)

Country Status (10)

Country Link
US (1) US20040220277A1 (cg-RX-API-DMAC7.html)
EP (1) EP1626709B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006517232A (cg-RX-API-DMAC7.html)
KR (1) KR20050119106A (cg-RX-API-DMAC7.html)
AT (1) ATE372112T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004210671A1 (cg-RX-API-DMAC7.html)
CA (1) CA2515394A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004008771T2 (cg-RX-API-DMAC7.html)
ES (1) ES2293223T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004071501A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
EP1874274A2 (en) * 2005-04-06 2008-01-09 Mallinckrodt Inc. Matrix-based pulse release pharmaceutical formulation
WO2007041571A1 (en) * 2005-10-03 2007-04-12 Cambrex Charles City, Inc. Improved method of making amphetamine free base
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
US10463633B2 (en) * 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2013059676A1 (en) * 2011-10-21 2013-04-25 Subhash Desai Compositions for reduction of side effects
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
IL288554B2 (en) * 2016-02-24 2024-02-01 Chemapotheca LLC Controlled release of amphetamine, drug meters and dosage forms with abuse deterrence
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
CA3221280A1 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
CA3239514A1 (en) * 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056968A (en) * 1997-03-11 2000-05-02 Darwin Discovery Limited Pharmaceutical drug dosage forms providing different release rates
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
TWI291871B (en) * 2000-11-01 2008-01-01 Cognition Pharmaceuticals Llc Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning
AU2003208170B2 (en) * 2002-02-28 2006-11-23 Birseck Pty Ltd Treatment of effect of chemicals with their ultradilute stereoisomers
AU2003231156A1 (en) * 2002-04-30 2003-11-17 Npd Llc Multi-phasic delivery via transmucosal absorption of appetite suppressants and craving reduction medicaments
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts

Also Published As

Publication number Publication date
ES2293223T3 (es) 2008-03-16
KR20050119106A (ko) 2005-12-20
WO2004071501A1 (en) 2004-08-26
DE602004008771D1 (de) 2007-10-18
CA2515394A1 (en) 2004-08-26
HK1091117A1 (en) 2007-01-12
EP1626709B1 (en) 2007-09-05
DE602004008771T2 (de) 2008-06-12
EP1626709A1 (en) 2006-02-22
US20040220277A1 (en) 2004-11-04
JP2006517232A (ja) 2006-07-20
AU2004210671A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
DE602004008771D1 (de) Enantiomere amphetamine enthaltende zusammensetzungen zur behandlung von aufmerksamkeitsdefizit-/hyperaktivitätsstörung (adhd)
DE122005000011I1 (de) Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen.
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
BR0215517A (pt) Composição anti-séptica, e, métodos para desinfetar tecido e para produzir uma composição anti-séptica
DE60207383D1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
FR2873379B1 (fr) Procede de preparation d'acide hyaluronique reticule, acide hyaluronique reticule susceptible d'etre obtenu par ledit procede, implant contenant ledit acide hyaluronique reticule, et son utilisation
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE60118956D1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
NO20064373L (no) 5-aminolevulinsyresalt, fremgangsmate for dets fremstilling og anvendelse derav
ATE306915T1 (de) Verwendung eines kombinationspräparates aus vitamin-d-metaboliten oder vitamin-d-analoga und eines östrogenpartialagonisten zur behandlung von osteoporose
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
BRPI0408680A (pt) processo para produzir álcoois e aminas enantiomericamente enriquecidos
SE0203300D0 (sv) Novel Compounds
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
SE0101256D0 (sv) Treatment of low back pain
EA200600502A1 (ru) Способ асимметрической гидрогенизации бета-аминокетонов
ATE423201T1 (de) Antiandrogen-oligonukleotide zur behandlung von androgen-verwandten hautkrankheiten, diese verbindungen enthaltende pharmazeutische zusammensetzungen und deren verwendung
DE69922174D1 (de) Biomaterial zur behandlung von zahnfäule
DE60022033D1 (de) Therapeutische verwendung von d-threo-methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen
DE60313785D1 (de) Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen.
ATE442122T1 (de) Dentalmaterial mit bakteriostatischen und/oder bakteriziden substanzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties